logo
My Ever-Evolving Eye Health and Retinopathy Story

My Ever-Evolving Eye Health and Retinopathy Story

Health Line6 days ago
Losing my eyesight because of type 1 diabetes has always been the greatest fear of my life. Now, more than four decades after my T1D diagnosis and many years after my initial retinopathy diagnosis, diabetes is starting to steal my vision.
And I'm scared as hell.
Over the past 5 years, I've had 16 laser treatments and 6 injections in my eyes. Thinking about those numbers makes my mind spin. I worry whether, at some point, my eyes will just decide to give up.
Recently, I've been dealt a new diagnosis card: glaucoma. This complicates my already precarious state of life with both diabetes-related retinopathy and diabetic macular edema (DME). I now need to take eye drops twice a day to help lower the pressure in my eyes and prevent vision loss.
I've had diminished vision in my right eye since early 2024. There are dark floaters, almost like I'm looking through a thin veil placed in front of that eye. I can still see, but there are times when I close that eye just to get a break from that veil effect for a few brief moments, especially on clear sunny days or when I'm looking at bright screens.
There is a lot happening in my eye health journey, to say the least.
Fear of complications
For a dozen years after my initial retinopathy diagnosis, my condition was considered very mild and didn't require any attention beyond the best-possible blood sugar management.
But the fear of something more significant has always been there, lurking.
Many people with diabetes (PWDs) live in fear of the dreaded diabetes complications that could someday strike — especially those of us diagnosed with T1D as kids or teens, who've had many years for possible complications to develop.
There is a term in our circle called ' fear of hypoglycemia.' It's used to describe the experience of dreading low blood sugars so much that it negatively impacts your diabetes management. In a frantic effort to avoid lows, people with diabetes often let themselves run high, which increases the likelihood of complications.
Diagnosis Diaries
'Of course, I was terrified by the idea of a scary needle moving toward my eye. But in reality, I barely noticed it.'
I would suggest a new term for consideration, 'fear of complications.'
So many of us shape our lives and our diabetes care based on that fear, that anticipation, that dread of future complications — or of current complications that may evolve and get worse. It has a real mental health impact. The psychosocial part of diabetes care is still in desperate need of improvement.
I've been hearing the warnings about diabetes complications for as long as I can remember — including the fact that people with diabetes are at higher risk of developing eye disease.
More than half of all people with diabetes will experience diabetes-related retinopathy or macular edema at some point in their lives. Other estimates put that number even higher, particularly for people with T1D.
Facing my worst diabetes fears
In the summer of 2019, I learned that I'd crossed some retinopathy-related threshold and my diagnosis had evolved into one requiring laser treatments. My world seemed to collapse. My heart started beating rapidly, and tears began to swell.
Even though the eye doctor assured me that the treatments would be 'very routine,' my mind could hardly process the news.
After being informed of my progressing retinopathy and the need for laser treatments, my fear of complications immediately clouded all rational thought. My eye doctor tried to reassure me, as did others who'd been through this type of laser treatment before. 'Calm down,' they advised. 'It'll be all right.'
And yet, I couldn't calm down. Understandably. I'd never gone through something like this firsthand.
Going into the procedure, my nerves were frayed. I barely slept the night before. And the drive to the eye clinic was excruciating.
My retinopathy laser treatment
Despite my fears, I went through with it.
I discovered that the actual procedure wasn't scary or painful at all. It turned out to be less inconvenient than even a normal diabetes eye exam, where you have to keep your eyes open while staring into ridiculously bright lights.
The procedure on my affected eye went something like this:
I was given numbing eye drops and drops to dilate my pupils.
I saw someone draw an X to mark the spot over my left eye — a safety precaution.
I placed my chin on the laser machine and looked into its light, focusing on a little dot while the doctor examined the insides of my eye. This wasn't scary, as it was no different than any other machine I'd had to rest my chin on in the past for routine eye exams.
Next, I saw 30 bright flashes of light that were—as my eye doctor had explained—about the same as seeing rapid camera flashes back-to-back. This part took about 20 minutes in total.
The whole procedure from start to finish was only about 45 minutes, with half that time devoted to sitting in a waiting room as my numbing and dilation drops did their job.
And that was it!
My first-ever experience with retinopathy laser treatment was a breeze. No pain, no big deal.
That's what my eye specialist had told me going into the procedure, but I didn't take his word for it. I should've listened and trusted him.
In terms of 'recovery' afterward, it was easy-peasy with no visual impact. My left eye just felt dilated. In the following hours, we went out for dinner and drinks without any issues (aside from some grimaces when a bright light hit me at the wrong angle).
It was also a nice bonus that my blood sugars didn't spike as a result of this procedure. The hour or so before the treatment, I did experience higher blood sugars because of the stress and nervousness going into the appointment. But my blood sugar levels only rose to the low 200s before leveling off and settling back down within a couple of hours.
Over the next few days, my left eye was a bit itchy, and there were a handful of moments of minor discomfort from glaring at my bright laptop screen. But that was it.
Experiencing eye injections
That initial laser procedure was successful and treated the eye issue at hand. But it wouldn't be my last. My progressing retinopathy would soon lead to DME and require more treatments.
Almost a year after my first laser treatment, an eye hemorrhage materialized. I started noticing dark, black floaters in my right eye — the one that hadn't needed the initial laser treatment. Cue even more panic from me!
There was a lot of crying because this was the first and most noticeable time my vision had been impaired as a result of retinopathy.
My situation was described as a 'critical, vision-impacting emergency.' The retinal specialist observed that a small blood vessel had burst. Blood leakage in my retina was causing the floaters in my field of vision.
This required an eye injection.
Diagnosis Diaries
'Connecting to others who've gone through these types of treatments has been a saving grace, putting my nerves and mind at ease in the most stressful of times.'
There are several eye injection medications available for diabetes-related retinopathy, but my doctor suggested the oldest one on the market: Avastin.
Interestingly, Avastin isn't even approved for diabetes-related retinopathy or DME. It was previously used to treat cancer. Now it's used off-label for people with diabetes experiencing retinopathy-related vision issues, as it can slow or stop abnormal blood vessel growth. My eye specialist explained that it's a less expensive first-line treatment that's just as effective as the newer, more expensive injections.
Once again, my treatment began with numbing drops. But then came the injection.
Of course, I was terrified by the idea of a scary needle moving toward my eye. But in reality, I barely noticed it. Thankfully the injection comes from the side of your field of vision. And due to the numbing drops, I felt only a little pinch, lasting just a few seconds. It was finished just as quickly as it had begun.
Later in the day, once the eye drops had worn off, my sight was back to normal. There was some minimal burning at times, similar to the way it hurts looking into a bright light. It would force me to close my eyes for a moment to adjust while I wipe away some tears.
The blood in my eye that was causing the floaters eventually dissipated, as the doctor expected it would.
An evolving diagnosis
I've had several more injections and many more laser treatments since this started. This is a continuing journey with many moving parts:
Several of my appointments include dye tests, where they inject a yellow dye into my veins and then take detailed photos of the back of my eye to see how my blood vessels are faring.
With glaucoma, I also need to use eye drops twice a day to help keep my eye pressure low. Otherwise, there's a chance that I could suddenly lose my vision because of the glaucoma, not the diabetes-related retinopathy.
I'm also at higher risk for developing a detached retina thanks to family history and my own eye health issues, and so that is something I'm keeping in mind as I get older.
To date, I'm grateful everything has been going as well as it can. And I continue doing my best to keep my blood sugars in range.
Although no one wants to develop or need treatment for diabetes-related eye disease, I'm obviously hugely relieved about my (mostly) positive experience.
Even though I remain scared about losing my eyesight, I try to be mindful of the fact that there's a lot to be thankful for in living with diabetes in the here and now.
Mike Hoskins is an engagement editor at Healthline. Prior to that, he was managing editor at DiabetesMine. He has lived with type 1 diabetes since age 5 in 1984, and his mom was also diagnosed with T1D at the same young age.
With a journalism degree from Oakland University in Michigan, Mike has over two decades of experience at various daily, weekly, and specialty print and digital media publications. He joined DiabetesMine in 2012, after several years of writing his own personal blog, .
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

60 Degrees Pharmaceuticals to Submit MUMS (Minor Use/Minor Species) Designation Request to FDA for Tafenoquine for Acute Canine Babesiosis in 2025
60 Degrees Pharmaceuticals to Submit MUMS (Minor Use/Minor Species) Designation Request to FDA for Tafenoquine for Acute Canine Babesiosis in 2025

Yahoo

time34 minutes ago

  • Yahoo

60 Degrees Pharmaceuticals to Submit MUMS (Minor Use/Minor Species) Designation Request to FDA for Tafenoquine for Acute Canine Babesiosis in 2025

Data from three independent clinical studies demonstrate utility of tafenoquine to treat acute canine babesiosis WASHINGTON, July 14, 2025 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) ('60 Degrees' or the 'Company'), a pharmaceutical company focused on developing new medicines for infectious diseases, today announced that the Company will conduct a gap analysis of its existing data prior to submitting a Minor Use Minor Species (MUMS) designation request to the United States Food and Drug Administration (FDA) for tafenoquine for the treatment of acute canine babesiosis. The submission will be based on results of three clinical efficacy studies that evaluated ARAKODA® (tafenoquine) for canine babesiosis, and existing canine safety data and chemistry manufacturing and controls (CMC) data for tafenoquine generated through the clinical development of ARAKODA for malaria. The clinical efficacy studies involved experimental Babesia infections and dogs diagnosed with naturally acquired Babesia infection in veterinary clinics. One of the studies was company-sponsored and conducted at North Carolina State University. Collectively, the studies showed that tafenoquine, administered as ARAKODA tablets, was well tolerated and appeared to facilitate recovery from acute infection. Every year in the United States, several hundred to several thousand cases of canine babesiosis are seen. It is an emerging tick-borne illness carried by the same tick vector as Lyme Disease. No FDA-approved oral treatment for canine babesiosis exists, and currently available treatments carry significant toxicity risk or the propensity to generate drug resistance. 'Data from the canine babesiosis studies are impactful when viewed in the larger context of the ground-breaking human babesiosis research we are now sponsoring,' said Chief Executive Officer of 60 Degrees Pharmaceuticals, Geoff Dow. 'The positive findings of the canine babesiosis study are in line with our earlier findings that tafenoquine could be effective against babesiosis in humans.' About ARAKODA® (tafenoquine)Tafenoquine was discovered by Walter Reed Army Institute of Research. Tafenoquine was approved for malaria prophylaxis in 2018 in the United States as ARAKODA® and in Australia as KODATEF®. Both were commercially launched in 2019 and are currently distributed through pharmaceutical wholesaler networks in each respective country. They are available at retail pharmacies as a prescription-only malaria prevention drug. According to the Centers for Disease Control and Prevention, the long terminal half-life of tafenoquine, which is approximately 16 days, offers the advantage of less frequent dosing for the prophylaxis of malaria. ARAKODA® is not suitable for everyone, and patients and prescribers should review the Important Safety Information below. Individuals at risk of contracting malaria are prescribed ARAKODA® 2 x 100 mg tablets once per day for three days (the loading phase) prior to travel to an area of the world where malaria is endemic, 2 x 100 mg tablets weekly for up to six months during travel, then 2 x 100 mg in the week following travel. Tafenoquine has not been proven to be effective for treatment or prevention of babesiosis and is not approved by the U.S. Food and Drug Administration for such an indication. ARAKODA® (tafenoquine) Important Safety Information ARAKODA® is an antimalarial indicated for the prophylaxis of malaria in patients aged 18 years and older. Contraindications ARAKODA® should not be administered to: Glucose-6-phosphate dehydrogenase ('G6PD') deficiency or unknown G6PD status; Breastfeeding by a lactating woman when the infant is found to be G6PD deficient or if G6PD status is unknown; Patients with a history of psychotic disorders or current psychotic symptoms; or Known hypersensitivity reactions to tafenoquine, other 8-aminoquinolines, or any component of ARAKODA®. Warnings and Precautions Hemolytic Anemia: G6PD testing must be performed before prescribing ARAKODA® due to the risk of hemolytic anemia. Monitor patients for signs or symptoms of hemolysis. G6PD Deficiency in Pregnancy or Lactation: ARAKODA® may cause fetal harm when administered to a pregnant woman with a G6PD-deficient fetus. ARAKODA® is not recommended during pregnancy. A G6PD-deficient infant may be at risk for hemolytic anemia from exposure to ARAKODA® through breast milk. Check infant's G6PD status before breastfeeding begins. Methemoglobinemia: Asymptomatic elevations in blood methemoglobin have been observed. Initiate appropriate therapy if signs or symptoms of methemoglobinemia occur. Psychiatric Effects: Serious psychotic adverse reactions have been observed in patients with a history of psychosis or schizophrenia, at doses different from the approved dose. If psychotic symptoms (hallucinations, delusions, or grossly disorganized thinking or behavior) occur, consider discontinuation of ARAKODA® therapy and evaluation by a mental health professional as soon as possible. Hypersensitivity Reactions: Serious hypersensitivity reactions have been observed with administration of ARAKODA®. If hypersensitivity reactions occur, institute appropriate therapy. Delayed Adverse Reactions: Due to the long half-life of ARAKODA® (approximately 16 days), psychiatric effects, hemolytic anemia, methemoglobinemia, and hypersensitivity reactions may be delayed in onset and/or duration. Adverse Reactions: The most common adverse reactions (incidence greater than or equal to 1 percent) were: headache, dizziness, back pain, diarrhea, nausea, vomiting, increased alanine aminotransferase (ALT), motion sickness, insomnia, depression, abnormal dreams, and anxiety. Drug Interactions Avoid co-administration with drugs that are substrates of organic cation transporter-2 or multidrug and toxin extrusion transporters. Use in Specific Populations Lactation: Advise women not to breastfeed a G6PD-deficient infant or infant with unknown G6PD status during treatment and for 3 months after the last dose of ARAKODA®. To report SUSPECTED ADVERSE REACTIONS, contact 60 Degrees Pharmaceuticals, Inc. at 1- 888-834-0225 or the FDA at 1-800-FDA-1088 or The full prescribing information of ARAKODA® is located here. About 60 Degrees Pharmaceuticals, Inc.60 Degrees Pharmaceuticals, Inc., founded in 2010, specializes in developing and marketing new medicines for the treatment and prevention of infectious diseases that affect the lives of millions of people. 60 Degrees Pharmaceuticals, Inc. achieved FDA approval of its lead product, ARAKODA® (tafenoquine), for malaria prevention, in 2018. 60 Degrees Pharmaceuticals, Inc. also collaborates with prominent research organizations in the U.S., Australia, and Singapore. The 60 Degrees Pharmaceuticals, Inc. mission has been supported through in-kind funding from the U.S. Department of Defense and private institutional investors including Knight Therapeutics Inc., a Canadian-based pan-American specialty pharmaceutical company. 60 Degrees Pharmaceuticals, Inc. is headquartered in Washington D.C., with a majority-owned subsidiary in Australia. Learn more at The statements contained herein may include prospects, statements of future expectations and other forward-looking statements that are based on management's current views and assumptions and involve known and unknown risks and uncertainties. Actual results, performance or events may differ materially from those expressed or implied in such forward-looking statements. Cautionary Note Regarding Forward-Looking StatementsThis press release may contain 'forward-looking statements' within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward‐looking statements reflect the current view about future events. When used in this press release, the words 'anticipate,' 'believe,' 'estimate,' 'expect,' 'future,' 'intend,' 'plan,' or the negative of these terms and similar expressions, as they relate to us or our management, identify forward‐looking statements. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy, activities of regulators and future regulations and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: there is substantial doubt as to our ability to continue on a going-concern basis; we might not be eligible for Australian government research and development tax rebates; if we are not able to successfully develop, obtain FDA approval for, and provide for the commercialization of non-malaria prevention indications for tafenoquine (ARAKODA® or other regimen) or Celgosivir in a timely manner, we may not be able to expand our business operations; we may not be able to successfully conduct planned clinical trials or patient recruitment in our trials might be slow or negligible; and we have no manufacturing capacity which puts us at risk of lengthy and costly delays of bringing our products to market. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's filings with the Securities and Exchange Commission ('SEC'), including the information contained in our Annual Report on Form 10-K filed with the SEC on April 1, 2024, and our subsequent SEC filings. Investors and security holders are urged to read these documents free of charge on the SEC's website at As a result of these matters, changes in facts, assumptions not being realized or other circumstances, the Company's actual results may differ materially from the expected results discussed in the forward-looking statements contained in this press release. Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise. Media Contacts:Sheila A. BurkeSheilaBurke-consultant@ 667-6330 Investor Contact:Patrick Gaynespatrickgaynes@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

New Jersey woman nearly dies after taking dangerous amount of popular supplement: ‘I was very, very, very scared'
New Jersey woman nearly dies after taking dangerous amount of popular supplement: ‘I was very, very, very scared'

Yahoo

timean hour ago

  • Yahoo

New Jersey woman nearly dies after taking dangerous amount of popular supplement: ‘I was very, very, very scared'

A New Jersey woman says she almost died after taking daily turmeric pills, a popular supplement found in grocery stores. Katie Mohan, a 57-year-old from Morristown, told she sustained liver damage after taking daily pills of turmeric, a yellow spice widely used for its antioxidant and anti-inflammatory properties. Mohan said her first symptoms included fatigue, nausea, stomach pain and yellowing eyes, which are a sign of jaundice. Mohan first saw her doctor in April, but the scans and tests ordered came back normal. Her symptoms continued to get worse until June, when Mohan read an NBC News story about a man with similar symptoms who found out he had a drug-induced liver injury after taking turmeric daily. 'I threw [the supplements] out, and I said to myself, 'I'm wondering if this is what's causing my symptoms,'' Mohan told Mohan bought the turmeric pills, which were manufactured by YouTheory, at Costco, reports. The product states the daily dose is three pills containing 2,250 milligrams, Mohan said, which is over the World Health Organization's recommendation of up to 3 milligrams per kilogram of body weight per day. A New Jersey woman says she damaged her liver by taking daily turmeric supplements (Getty Images) After reading the NBC News article, Mohan went to urgent care. From there, she was admitted to Morristown Medical Center, where doctors found that she had severe liver damage. She was treated with an antiviral IV drip, but her skin was still yellowing. Mohan recalled thinking: 'Am I going to need a liver transplant? Am I going to die?' 'I was very, very, very scared,' she added. That's when she was transferred to NYU Langone in New York. There, her doctor found 'evidence of acute hepatitis, impending liver failure and potential transplant evaluation.' 'She was really very sick,' Dr. Nikolaos Pyrsopoulos, told 'Her liver numbers were 60 to 70 times above the normal limit. And she was very yellow.' Mohan said Pyrsopoulos confirmed her fears that the turmeric caused her symptoms. Katie Mohan said she was worried she would need a liver transplant after taking too much turmeric (Getty Images) 'He's like, 'You essentially poisoned the liver with the turmeric,'' she said. 'It was the dose combined with the fact that it had that black pepper in it.' Pyrsopoulos told that his hospital sees three to four liver transplants per year related to turmeric poisoning. Mohan has since been discharged and says her liver enzyme levels are still elevated, but they're continuing to fall and her symptoms have completely disappeared. Mohan has since reported the supplements to the Food and Drug Administration. The Independent has contacted Costco and YouTheory for comment.

New York official again rebuffs Texas judgment against doctor over abortion pills
New York official again rebuffs Texas judgment against doctor over abortion pills

Yahoo

timean hour ago

  • Yahoo

New York official again rebuffs Texas judgment against doctor over abortion pills

By Daniel Wiessner (Reuters) -A county official in New York on Monday rejected for a second time efforts by Texas to enforce a $100,000 judgment against a New York doctor accused of violating Texas' ban on abortion by sending abortion pills to the state, further escalating an unprecedented interstate conflict. Acting Ulster County Clerk Taylor Bruck in a letter to the office of Republican Texas Attorney General Ken Paxton doubled down on his March finding that New York's so-called shield law precludes the enforcement of other states' abortion bans against New Yorkers. Paxton's office last week had asked Bruck to reconsider, arguing that he had a legal duty to enforce the judgment against New Paltz, New York-based doctor Margaret Carpenter. Bruck on Monday said Paxton's office had not presented any new information. "While I'm not entirely sure how things work in Texas, here in New York, a rejection means the matter is closed," wrote Bruck, who is running for county clerk as a Democrat. Paxton's office and the Abortion Coalition for Telemedicine, a group co-founded by Carpenter, did not immediately respond to requests for comment. New York Governor Kathy Hochul, a Democrat who championed the passage of the shield law earlier this year, praised Bruck for "defending the freedom generations of women fought to secure." "Our response to (Texas') baseless claim is clear: no way in hell. New York won't be bullied," Hochul said in a statement. Medication abortion accounts for more than half of U.S. abortions. It has drawn increasing attention since the U.S. Supreme Court's 2022 decision allowing states to ban abortion, which more than 20 states, including Texas, have done. A judge in Collin County, Texas, entered a default judgment against Carpenter in February after she failed to respond to the state's civil lawsuit alleging she illegally prescribed mifepristone and misoprostol, the two drugs used in medication abortion, to a Texas woman via telemedicine. Carpenter has also been indicted by a Louisiana grand jury for prescribing an abortion pill that was taken by a teenager there, in what appeared to be the first time a state criminally charged a doctor in another state for prescribing abortion drugs. Hochul in February rejected Louisiana's request to extradite Carpenter there.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store